PumpTune computer recommended insulin pump settings compared to Doctor advised settings in children with Type 1 Diabetes: A randomised controlled trial
Phase 2
Completed
- Conditions
- Type 1 diabetesMetabolic and Endocrine - Diabetes
- Registration Number
- ACTRN12614001330639
- Lead Sponsor
- Dr Donald Anderson
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
HbA1c in range 6.5-9.5%
Diabetes was diagnosed at least 12 months previously
Performing >=4 finger prick blood glucose levels each day
Delivering at least six bolus doses of insulin each day
Exclusion Criteria
Not able to attend John Hunter Hospital for three consecutive weeks to have sensors inserted and pumps adjusted
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method percentage of time sensor glucose levels remain within range 3.9-10.0mmol/L as assessed by analysis of data exported from continous glucose sensor.[over 6 days observation]
- Secondary Outcome Measures
Name Time Method percentage time sensor glucose levels remain >=10mmo//L as assessed by analysis of data exported from continous glucose sensor. [over 6 days observation];percentage time sensor glucose levels remain <=3.9mmo//L as assessed by analysis of data exported from continous glucose sensor.[over 6 days observation];Number of times sensor glucose levels fall below 2.75mmol/L as assessed by analysis of data exported from continous glucose sensor.[over 6 days observation]
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does the PumpTune algorithm optimize insulin delivery compared to physician-adjusted settings in pediatric Type 1 Diabetes cross-over trials?
What glycemic variability outcomes were observed in ACTRN12614001330639 comparing computerized vs. manual insulin pump adjustments?
Which biomarkers (e.g., C-peptide, HbA1c) predict response to algorithm-driven insulin pump settings in children with T1D?
What adverse events (hypoglycemia, hyperglycemia) occurred during ACTRN12614001330639's Phase II pediatric insulin pump trial?
How does PumpTune's closed-loop system compare to other automated insulin delivery platforms like the MiniMed 670G in pediatric populations?